Skip to main content
. Author manuscript; available in PMC: 2018 Nov 5.
Published in final edited form as: J Solid Tumors. 2017;7(2):7–13. doi: 10.5430/jst.v7n2p7

Table 3.

Initial management and change in management

Patient # Inintial manangement Change in management
1 None Doxil, Cytoxan
2 None Paclitaxel, Carboplatin, Tarceva
3 Temodar, Thalidomide Docetaxel
4 None Temodar
5 None Chemotherapy
6 None Chemotherapy
7 None Docetaxil, Caroplatin
8 Pemetrexed, Carboplatin Erlotinib
9 None Folfiri, Avastin
10 None Thyroidectomy, bilateral neck dissection
11 None Emetrexed, Carboplatin
12 None Arboplatin, Paclitaxel
13 None Xeloda
14 None Hospice
15 None Carboplatin, Certuximab
16 None Capecitabine, Ixabepilone
17 None Carboplatin, Paclitaxel
18 Trastuzumb, Arimidex Trastuzumab, radiation
19 None Erbitux with Gemcitabine
20 None Lost to follow-up
21 None Taxotere, Cisplatin, Tarceva
22 Aarimidex Ixabepilone, Bevacizumab
23 None Pemetrexed, Carboplatin,Bevacizumab
24 None Doxetaxel, Cisplatin